EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Inhibrx Biosciences, Inc.
INBX

INBX Inhibrx Biosciences Inc.

Inhibrx Biosciences Inc. · NASDAQ
Market Closed
109.27
▼ ⁦-1.93%⁩ (-2.15)
Market Cap$1.6B
Beta3.52
52w Low52w High
26.19155.29
Last Week
⁦-12.35%⁩
Last Month
⁦+27.37%⁩
Last 3 Months
⁦+5.06%⁩
Last Year
⁦+298.80%⁩
EL7 Factor Analysis
How we score this
Overall17
Poor — bottom quartile of the marketMomentum TrapF 4/9Insider cluster buyBetter than 17% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
20
—17.8xBottom tier
▸
Growth
14
-100.0%▼7.1%Bottom tier
▸
Quality
3
—4.5%Bottom tier
▸
Safety
5
—2.6xBottom tier
▸
Capital Return
88
—2.12%Top tier
▸
Momentum
83
223.6%▲2.9%Top tier
▸
Sentiment
86
2▼3Top tier

Frequently Asked Questions

What is Inhibrx Biosciences, Inc. stock?▼

Inhibrx Biosciences, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in Inhibrx Biosciences, Inc.?▼

You can buy Inhibrx Biosciences, Inc. shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating Inhibrx Biosciences, Inc.?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does Inhibrx Biosciences, Inc. pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in Inhibrx Biosciences, Inc.?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.

Fair Value
Low confidenceCurrent price$109
Analyst target · 1 analysts
$285
—
Range ⁦$245–$325⁩
vs
DCF (estimate)
N/A (negative FCF)

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener

AI analysis from the earnings call, financials and news

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 1 analysts setting price target
$285.00
⁦+160.8%⁩
Current Price $109.27·Median $285.00
Low
$245.00
High
$325.00
Current price
$109.27
Average target
$285.00
Street summary

Price Target Revision for Inhibrx Biosciences (INBX)

The stock saw a reduction in its consensus price target from $325 to $285 over the past thirty days, representing a decline of 12.31%. Despite this reduction, the price target still reflects significant optimism compared to the current price of $122.26. This adjustment coincided with diverging views from research institutions; H.C. Wainwright initiated coverage with a "Buy" rating on August 24, while Citigroup maintained a "Hold" rating on August 27.

As of 2026-09-03
Revisions momentum · 30d
⁦-12.3%⁩
Average rating
★ 3.75
Buy
Analyst coverage
4
Buy conviction
75%
High
Rating activity · 30d
0↑ · 0↓
Target dispersion
73%
Wide
Analyst ratings over time4 analysts rating
3
1
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months3.67 → 3.75
Recent analyst moves
  • = Reiterate2026-08-27
    Citigroup
    Market Perform
  • = Reiterate2026-08-24
    H.C. Wainwright
    Buy
  • = Reiterate2026-05-15
    Stifel Nicolaus
    —· $325.00
Premium content
Financial Analysis
|